Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31608387 | 1.00 | NR1H4 (0.72) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348566 | 0.89 | NR1H4 (0.75) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22347509 | 0.88 | NR1H4 (0.75) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL29458325 | 0.88 | NR1H4 (0.76) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348643 | 0.88 | NR1H4 (0.76) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348554 | 0.88 | NR1H4 (0.72) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348573 | 0.87 | NR1H4 (0.74) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL31608395 | 0.87 | NR1H4 (0.74) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348654 | 0.87 | NR1H4 (0.71) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348740 | 0.87 | NR1H4 (0.73) | NR1H4NR1I2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | claimed |
| EP-3924333-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2020168149-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | claimed |
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3924333-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168149-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | NR1H4 1/4885NR1I2 12/4885CYP2C19 2122/4885 |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885NR1I2 9/4885CYP2C19 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.